share_log

复宏汉霖(02696.HK):HLX78(拉索昔芬片)联合阿贝西利对比氟维司群联合阿贝西利用于局部晚期或转移性乳腺癌的国际多中心3期临床研究完成中国大陆首例患者给药

HENLIUS (02696.HK): The international multicenter phase 3 clinical study comparing HLX78 (lasofoxifene tablets) in combination with abemaciclib to fulvestrant in combination with abemaciclib for locally advanced or metastatic breast cancer has completed t

Gelonghui Finance ·  Dec 24 17:35

On December 24, Gelonghui reported that HENLIUS (02696.HK) announced that recently, an international multicenter phase III clinical trial entitled "ELAINE-3" comparing HLX78 (lasofoxifene) in combination with Abemaciclib and Fulvestrant for the treatment of pre/postmenopausal women and men with locally advanced or metastatic breast cancer who have previously received aromatase inhibitors (AI) in combination with Palbociclib or Ribociclib (as the first hormone treatment regimen for metastatic disease), estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-), and carrying estrogen receptor 1 (ESR1) mutations has completed the first patient dosing in mainland China. Currently, partner Sermonix Pharmaceuticals, Inc. is conducting the ELAINE-3 study globally, which has completed the first patient dosing worldwide in January 2024 and is also enrolling patients in the USA, Europe, Canada, and other regions.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment